-
08.27.2023 | Superbugs: why it’s so hard to stop the ‘silent pandemic’
FINANCIAL TIMES | Antimicrobial resistance already kills millions and is
projected to get worse. But there is little incentive for Big
Pharma to tackle the issue. -
08.23.2023 | CARB-X Receives Global Funding in Fight Against Antimicrobial Resistance
THE RECORD | New, multi-million dollar grants come from the British, German, and Canadian governments.
-
07.28.2023 | GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections
GARDP | GARDP and Bugworks Research Inc., an innovative clinical-stage biopharmaceutical company with research and development facilities in Bangalore, India, to accelerate the development of a new broad-spectrum antibiotic compound aimed at treating serious infections caused by multidrug-resistant bacteria.
-
05.15.2023 | New WHO report highlights progress, but also remaining gaps, in ensuring a robust pipeline of antibiotic treatments to combat antimicrobial resistance (AMR)
WHO | AMR was associated with nearly 5 million deaths in 2019, however the R&D pipeline for new antibiotics is thin and access to new and existing treatments remains a challenge.
-
05.07.2023 | Towards a reformed R&D ecosystem for infectious disease
WELLCOME | Antimicrobial resistance (AMR) R&D work inside the Bugworks’ facility in Bangalore, India.
-
03.30.2023 | Rapid Pathogen ID/AST Market Begins to Recover Post-COVID as Drug-Resistant Infections Spike
GENOME WEB | After pandemic-related setbacks, makers of rapid pathogen identification (ID) and antimicrobial susceptibility testing (AST) systems foresee a growing crisis of drug-resistant infections moving the needle on adoption of novel diagnostic approaches.
-
03.29.2023 | We’re Running Out of New Antibiotics, WHO Warns
GIZMODO | Experts with the World Health Organization have issued a dire warning about our never-ending battle against dangerous bacteria: The pipeline of new antibiotics, particularly those that can handle drug-resistant bacteria, is running dry. Only around two dozen candidates meant to treat important infections are currently thought to be in clinical trials, with even fewer potential drugs that can reliably take on superbugs in development.
-
03.28.2023 | A New Drug-Resistant Fungus Is Spreading in Hospitals. Is It The Last of Us in Real Life?
THE BRINK | Candida auris isn’t going to “cause a zombie apocalypse tomorrow,” says CARB-X director Kevin Outterson—but researchers do need to take it seriously
-
03.01.2023 | NBC NEWS | CDC warns about the rise in almost untreatable Shigella bacterial infections
The drug-resistant stomach bug, a major cause of inflammatory diarrhea, is a “serious public health threat.”
-
02.22.2023 | As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest
JAMA | During the COVID-19 pandemic, antibiotic-resistant infections increased significantly, leading physicians to seek alternative treatments such as phage therapy, a century-old method that uses viruses to selectively kill bacteria. Despite its controversial history and the rise of antibiotics, phage therapy is gaining attention as a potential solution to the growing problem of antibiotic resistance.
-
01.19.2023 | Interview with Dr. Su Chiang from CARB-X, a global antibiotic innovation accelerator
ANTIBIOTIC RESISTANCE AWARENESS PODCAST | Host Ethan Rhee has a special guest to kick off Season 2. Dr. Su Chiang is a Senior Alliance Manager at CARB-X, a global non-profit antibiotic innovation accelerator.
-
01.16.2023 | Lumen Bio: ‘We face 2023 with tremendous optimism’
BIOPHARMA REPORTER | Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.
Toggle navigation